AAAAAA

   
Results: 1-25 |
Results: 25

Authors: Estey, EH
Citation: Eh. Estey, Growth factors in acute myeloid leukaemia, BEST P R C, 14(1), 2001, pp. 175-187

Authors: Estey, EH
Citation: Eh. Estey, Prognostic factors in acute myelogenous leukemia, LEUKEMIA, 15(4), 2001, pp. 670-672

Authors: Bibawi, S Abi-Said, D Fayad, L Anderlini, P Ueno, NT Mehra, R Khouri, I Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Andreeff, M Andersson, BS Estey, EH Champlin, R Przepiorka, D
Citation: S. Bibawi et al., Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia, AM J HEMAT, 67(4), 2001, pp. 227-233

Authors: Beran, M Shen, Y Kantarjian, H O'Brien, S Koller, CA Giles, FJ Cortes, J Thomas, DA Faderl, S Despa, S Estey, EH
Citation: M. Beran et al., High-dose chemotherapy in high-risk myelodysplastic syndrome - Covariate-adjusted comparison of five regimens, CANCER, 92(8), 2001, pp. 1999-2015

Authors: Estey, EH
Citation: Eh. Estey, Therapeutic options for acute myelogenous leukemia, CANCER, 92(5), 2001, pp. 1059-1073

Authors: Giles, FJ Kantarjian, HM Kornblau, SM Thomas, DA Garcia-Manero, G Waddelow, TA David, CL Phan, AT Colburn, DE Rashid, A Estey, EH
Citation: Fj. Giles et al., Mylotarg(TM) (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation, CANCER, 92(2), 2001, pp. 406-413

Authors: Estey, EH Thall, PF Cortes, JE Giles, FJ O'Brien, S Pierce, SA Wang, XM Kantarjian, HM Beran, M
Citation: Eh. Estey et al., Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts, BLOOD, 98(13), 2001, pp. 3575-3583

Authors: Thall, PF Estey, EH
Citation: Pf. Thall et Eh. Estey, Graphical methods for evaluating covariate effects in the Cox model, HANDBOOK OF STATISTICS IN CLINICAL ONCOLOGY, 2001, pp. 411-432

Authors: Ibrahim, S Estey, EH Pierce, S Glassman, A Keating, M O'Brien, S Kantarjian, HM Albitar, M
Citation: S. Ibrahim et al., 11q23 Abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses, AM J CLIN P, 114(5), 2000, pp. 793-797

Authors: Estey, EH
Citation: Eh. Estey, Treatment of relapsed and refractory acute myelogenous leukemia, LEUKEMIA, 14(3), 2000, pp. 476-479

Authors: Estey, EH Pierce, S Keating, MJ
Citation: Eh. Estey et al., Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities, HAEMATOLOG, 85(3), 2000, pp. 246-249

Authors: Estey, EH
Citation: Eh. Estey, How I treat older patients with AML, BLOOD, 96(5), 2000, pp. 1670-1673

Authors: Estey, EH Shen, Y Thall, PF
Citation: Eh. Estey et al., Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB, BLOOD, 95(1), 2000, pp. 72-77

Authors: Weinkauff, R Estey, EH Starostik, P Hayes, K Huh, YO Hirsch-Ginsberg, C Andreeff, M Keating, M Kantarjian, HM Freireich, EJ Albitar, M
Citation: R. Weinkauff et al., Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia, AM J CLIN P, 111(6), 1999, pp. 733-740

Authors: Aboul-Nasr, R Estey, EH Kantarjian, HM Freireich, EJ Andreeff, M Johnson, BJ Albitar, M
Citation: R. Aboul-nasr et al., Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens, AM J CLIN P, 111(6), 1999, pp. 753-758

Authors: Estey, EH Thall, PF Reed, P Kantarjian, H Beran, M Pierce, S Keating, MJ
Citation: Eh. Estey et al., Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy, LEUKEMIA, 13(6), 1999, pp. 850-854

Authors: Seymour, JF Juneja, SK Campbell, LJ Ellims, PH Estey, EH Prince, HM
Citation: Jf. Seymour et al., Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensifiedara-C therapy, LEUKEMIA, 13(11), 1999, pp. 1735-1740

Authors: Andreeff, M Jiang, S Zhang, X Konopleva, M Estrov, Z Snell, VE Xie, Z Okcu, MF Sanchez-Williams, G Dong, J Estey, EH Champlin, RC Kornblau, SM Reed, JC Zhao, S
Citation: M. Andreeff et al., Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid, LEUKEMIA, 13(11), 1999, pp. 1881-1892

Authors: Thall, PF Lee, JJ Tseng, CH Estey, EH
Citation: Pf. Thall et al., Accrual strategies for phase I trials with delayed patient outcome, STAT MED, 18(10), 1999, pp. 1155-1169

Authors: Thall, PF Estey, EH Sung, HG
Citation: Pf. Thall et al., A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials, INV NEW DR, 17(2), 1999, pp. 155-167

Authors: Cortes, JE Kantarjian, HM O'Brien, S Giles, F Keating, MJ Freireich, EJ Estey, EH
Citation: Je. Cortes et al., A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission, CANCER, 85(7), 1999, pp. 1506-1513

Authors: Estrov, Z Manna, SK Harris, D Van, Q Estey, EH Kantarjian, HM Talpaz, M Aggarwal, BB
Citation: Z. Estrov et al., Phenylarsine oxide blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappa B, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells, BLOOD, 94(8), 1999, pp. 2844-2853

Authors: Estey, EH Giles, FJ Kantarjian, H O'Brien, S Cortes, J Freireich, EJ Lopez-Berestein, G Keating, M
Citation: Eh. Estey et al., Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia, BLOOD, 94(7), 1999, pp. 2230-2235

Authors: Estey, EH Thall, PF Pierce, S Cortes, J Beran, M Kantarjian, H Keating, MJ Andreeff, M Freireich, E
Citation: Eh. Estey et al., Randomized phase II study of fludarabine plus cytosine arabinoside plus idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome, BLOOD, 93(8), 1999, pp. 2478-2484

Authors: Konopleva, M Mikhail, A Estrov, Z Zhao, SR Harris, D Sanchez-Williams, G Kornblau, SM Dong, J Kliche, KO Jiang, SW Snodgrass, HR Estey, EH Andreeff, M
Citation: M. Konopleva et al., Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: Proliferative and anti-apoptotic activities, BLOOD, 93(5), 1999, pp. 1668-1676
Risultati: 1-25 |